Tandem Diabetes Q2 sales rise 8% to $240.7 million; net loss widens to $52.4 million
Tandem Diabetes reported second quarter 2025 worldwide sales of $240.7 million, up from $221.9 million a year earlier, but its GAAP net loss widened to $52.4 million from $30.8 million, including a $20.0 million litigation and settlement expense. The company also gave full-year 2025 guidance of about $1.0 billion in sales and a 53% to 54% gross margin, which matters to shareholders because it sets the company's expected revenue and margin path for the year.
Key points
- Q2 2025 worldwide sales were $240.7 million, including $70.5 million outside the United States, compared with $221.9 million in Q2 2024.
- GAAP net loss per share was $0.78, compared with $0.47 a year earlier; GAAP operating loss was $51.8 million.
- 2025 guidance calls for about $1.0 billion in sales, with about $700 million in the United States and about $300 million outside it.
- Adjusted EBITDA margin for 2025 was recast from about 3% to about negative 5%, reflecting an 8 percentage point impact from a first quarter acquired in-process research and development charge.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.